Three neonates born to three mothers with primary myxedema who have thyrotropin-binding inhibitor immunoglobulin (TBII) were continually examined after birth.
Recently, the presence of thyroid-stimulation blocking and thyrotropin-binding inhibitor immunoglobulin (blocking type TBII) in the serum of patients with primary myxedema was reported (Endo et al., 1978; Konishi et al., 1983) . And neonatal transient hypothyroidism due to maternal blocking type TBII has been reported (Matsuura et al., 1980; Iseki et al., 1983; Ninomiya et al., 1983; Takasu et al., 1984; Ishihara et al., 1985) . More recently, Arikawa et al. (1985) described three neonates delivered from different three mothers with primary myxedema. All three mothers had blocking type TBII, but one neonate showed transient hypothyroidism due to TBII. However, the other two neonates were euthyroid.
Recently, we experienced three neonates who were delivered from three mothers with blocking type TBII. Thus, we have attempted to clarify the relationship between the neonatal thyroid functions and thyroid- respectively, and TBII was 29% (Table 1) .
Results
Comparison of potency of TBII presented in serum of three mothers IgGs of patient 1-M, 2-M and 3-M were diluted by normal IgG, and dilution curves of inhibition of 125I-TSH binding to the receptor are shown in Figure 2 . The doses of IgGs that inhibited 1251-TSH binding to the level of 50% were 0.4, 0.7 and above 10mg/ml in patient 1-M, 2-M and 3-M. Patient 1-M, whose neonate developed hypothyroidism, had the most potent TBII activity.
Comparison of TSB activity in three mothers
The effect of IgGs prepared from three mothers and normal subject on TSH stimulation of thyroid adenylate cyclase was examined. Table 3 shows the dose-response results covering the dose range 5-20mg/ml obtained in the presence of 1 mU/ml TSH. At any concentration of IgG except at 10 mg/ml IgG of patient 3-M, the relative cAMP accumulations of three mothers were significantly lower than that of normal subjects. TSB activity of IgG prepared from patient 1-M was 2.6 and 15.7 times more potent than that of patient 2-M and of patient 3-M, respectively, at 10mg/ml IgG concentration.
And at 15mg/ml IgG concentration, TSB activity of patient 1-M was (1980), Iseki et al. (1983) , Ninomiya et al. (1983 ), Takasu et al. (1984 , and Ishihara et al. (1985) . The present family case is the sixth. The age of disappearance of the maternal TBII has been reported as three to ten months of age in previous reports. (Nakajima et al., 1985) .
Furthermore, we presented two euthyroid neonates born to two different mothers with primary myxedema who had blocking type TBII. Arikawa et al. (1985) reported that IgG of a mother who delivered transient hypothyroid neonates had 10-60 times more potent TBII activity and a much stronger inhibitory effect on TSH-stimulated adenylate cyclase activity than those of two mothers who delivered euthyroid neonates. In our report, IgG of patient 1-M who delivered transient hypothyroid neonate had 1.75 and above 25 times more potent TBII activity than that of patient 2-M and patient 3-M, respectively. And TSB activity of patient 1-M's IgG was 1.6-2.6 times more potent than patient 2-M's IgG and 7.1-15.7 times more than patient 3-M's IgG. This result suggests that thyroid function of neonate born to primary myxedema with positive blocking type TBII is influenced by the potency of TBI and TSB activity of mother. Patient 3 had almost the same TBII activity as that of his mother, and yet his thyroid function was normal.
One possibility is that TSB activity of patient 3 was less than that of his mother. His TSB activity could not be compared to that of his mother, because an in sufficent blood sample was taken from patient 3. Another possibility is that the sensitivity of neonatal thyroid to TBII in vivo was different from that of mothers. Further studies are required for to clarify the heterogeneity of blocking type TBII. 
